eli lilly semaglutide An Analyst Just Declared the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right? Novo Nordisk to offer obesity
Description
Amylin diabetes therapy is making a comeback as researchers develop a new generation of drugs designed to improve blood glucose control and support weight management
doi:10.1200/JCO.2026.44.16_suppl.11000 Shah Z, Hundal J, Afridi SS, et al
With diabetes and CKD projected to be the seventh and fifth leading cause of premature mortality worldwide by 2040, respectively [7], novel and effective treatment options are critical
Soules, and Nancy A
Studies on other addictive drugs are needed
However, in the high GLP-1 group, the change from baseline in the early (30-minute) LS-mean insulin response to OGTT was increased significantly at 12 weeks of treatment compared to the low GLP-1 groups [between group difference 31.13 U/ml (95% CI 9.94, 52.33 U/ml)
